Incidence and characteristics of naloxone administration in medical oncology patients with cancer pain

Journal of Pharmaceutical Care in Pain and Symptom Control

Volumn 8, Issue 2, 2000, Pages 65-73

  Cleary, James ^a,c   Gordon, Debra B ^a   Hutson, Paul ^a   Ward, Sandra ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antagonist; Audit; Cancer; Drug use evaluation; Naloxone; Oncology; Opioid; Outcome

Indexed keywords

FENTANYL; HALOPERIDOL; HYDROMORPHONE; MORPHINE; MORPHINE SULFATE; NALOXONE; OPIATE; PERCOCET;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DRUG OVERDOSE; FEMALE; HUMAN; INCIDENCE; MALE; RESPIRATORY FAILURE;

EID: 0033838238     PISSN: 10564950     EISSN: None     Source Type: Journal    
DOI: 10.1300/J088v08n02_05     Document Type: Article

References (6)

1. Incidence and characteristics of pain in a sample of medical-surgical patients
2. Pain and its treatment in outpatients with metastatic cancer
3. Quality improvement guidelines for the treatment of acute pain and cancer pain
4. Continuous infusion of naloxone in the treatment of narcotic overdose
5. Two cases of naloxone induced pulmonary oedema-the possible use of phentolamine in management
6. Treatment of pain at end of life: A position statement from the American Pain Society